Shield Thera Regulatory News (STX)

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

2015 Annual Report and Accounts and AGM Notification

London, UK, 30 June 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical Company focused on secondary care, gives notice that copies of the 2015 Annual Report and Accounts have been sent to shareholders. This document is available on the "Investors" section of the Company's website at www.shieldtherapeutics.com. Shield announced preliminary results for the year ended 31 December 2015 on 14 June 2016.

Further copies of the Annual Report will be available from the Company Secretary, Shield Therapeutics, Northern Design Centre, Gateshead Quays, NE8 3DF.

Shield also announces that its Annual General Meeting will be held on 4 August 2016. The meeting will be held at Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH, commencing at 10.00 am. Notice of the Annual General Meeting will be sent to shareholders by Monday 11th July 2016.

- Ends -

For further information please contact:

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The Company has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA). In addition, the Company has a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia), PT20. Shield, based in London and Newcastle, joined LSE's AIM in 2016 under the ticker STX. For more information please visit www.shieldtherapeutics.com.